Director Jason Rhodes Sells $65.2M in Dyne Stock via 10b5-1 Plan
DYN has more than doubled off its 52-week low of $11.645.
Summary
Director Jason Rhodes sold $65.2 million of Dyne Therapeutics stock under a pre-arranged 10b5-1 trading plan, reducing his indirect holdings while retaining a substantial position.
Key Events · Ownership and Investor Activity · DYN
-
Director Sells $65.2M in Stock
Jason P. Rhodes sold 2,586,928 shares for $65,184,894.40 on August 13-14, 2026, at prices ranging from $25.00 to $26.20 per share.
-
10b5-1 Plan Execution
The sales were executed under a Rule 10b5-1 trading plan adopted on July 13, 2026, indicating the transactions were pre-planned rather than discretionary.
-
Post-Sale Holdings
Rhodes retains 3,801,128 shares indirectly through various Atlas Venture funds, representing a substantial ongoing stake in the company.
-
Near 52-Week High
The sales occurred with the stock trading near its 52-week high of $27.31, suggesting the insider capitalized on recent price strength.
Analysis · DYN · Life Sciences
A significant insider sale at Dyne Therapeutics has just been disclosed. Director Jason P. Rhodes sold 2,586,928 shares for $65.2 million on August 13-14, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted July 13, 2026. The transactions occurred near the stock's 52-week high of $27.31, with prices ranging from $25.00 to $26.20. While the sales are substantial, they were executed under a pre-planned trading arrangement, which reduces the signal of insider conviction. Rhodes retains 3,801,128 shares, indicating a continued stake. The company recently completed a $375 million follow-on offering and received FDA Priority Review for its lead candidate, providing context for the stock's strength.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1516 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYN was trading at $26.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $11.65 to $27.31. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.